1422423-23-1

Emicoron is a multi-targeting G4 ligand. Emicoron showed Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer. EMICORON showed a marked therapeutic efficacy, as it inhibited the growth of patient-derived xenografts (PDX) and orthotopic colon cancer and strongly reduced the dissemination of tumor cells to lymph nodes, intestine, stomach, and liver. EMICORON had an unprecedented antitumor activity warranting further studies of EMICORON-based combination treatments.

Emicoron is a new promising G4 ligand and bind G-rich oncogene promoters. Emicoron possesses a marked antitumoral activity? alone or in combination with chemotherapeutics in vivo. Emicoron can be used for cancer research[1].

[1] Manuela Porru, et al. EMICORON: A multi-targeting G4 ligand with a promising preclinical profile. Biochim Biophys Acta Gen Subj. 2017 May; 1861(5 Pt B):1362-1370. DOI:10.1016/j.bbagen.2016.11.010